Abe H, Suzuka H, Tasaki H, Kuroiwa A
Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Jpn Heart J. 1995 Jul;36(4):483-7. doi: 10.1536/ihj.36.483.
A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release procainamide (750 mg/day). The plasma concentrations of procainamide and N-acetyl procainamide were at subtherapeutic levels. Discontinuation of procainamide led to complete recovery. A bone marrow aspiration showed slight hypoplasia with normocellular marrow. Lupus erythematosus (LE) and antinuclear antibody (ANA) tests were negative. The frequency and relationship of granulocytopenia caused by sustained-release procainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. Precautionary measures for the early recognition of this grave hazard in exposed patients are advocated. The physician should be aware of this complication before in initiating treatment with this drug.
一名71岁阵发性心房颤动男性患者,既往有前壁心肌梗死病史,口服缓释普鲁卡因胺(750毫克/天)8天后出现粒细胞减少。普鲁卡因胺和N - 乙酰普鲁卡因胺的血浆浓度处于亚治疗水平。停用普鲁卡因胺后完全康复。骨髓穿刺显示骨髓轻度发育不全,细胞数量正常。红斑狼疮(LE)和抗核抗体(ANA)检测均为阴性。简要讨论了缓释普鲁卡因胺所致粒细胞减少在快速心律失常患者中的发生频率及关系,并回顾了既往报道的病例。提倡采取预防措施以便早期识别暴露患者中的这一严重风险。医生在开始使用该药治疗前应知晓这一并发症。